CommentDPP-4 inhibitors and risk of heart failure EXAMINEd
References (10)
- et al.
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
Lancet Diabetes Endocrinol
(2014) - et al.
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo: the EXAMINE multicentre, randomised, double-blind trial
Lancet
(2015) - et al.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
N Engl J Med
(2013) - et al.
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
N Engl J Med
(2013) Saxagliptin, alogliptin, and cardiovascular outcomes
N Engl J Med
(2014)
Cited by (18)
Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies
2020, Diabetes Research and Clinical PracticeCitation Excerpt :Also a meta-analysis of the effects of DPP-4is on the single components of MACE did not show any beneficial signals with regard to MI, stroke, CV death, or the composite of MI and stroke [42]. Unexpectedly, heterogeneity was found regarding a till to date unexplained differential risk of hHF [1–4,43–47], with sitagliptin and linagliptin clearly not being associated with an increased rate of hHF [46–48]. As a clinical implication of these results, the latter two drugs have been named preferred treatment options in patients at increased risk for HF in current guidelines [22,23,48,49].
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
2017, American Journal of CardiologyCitation Excerpt :By contrast in the EXAMINE trial, which randomized 5380 T2DM patients with an acute coronary syndrome to receive alogliptin or placebo, the incidence of HF was comparable among the treatment arms (3.1% and 2.9%, respectively).54 However, post hoc analyses showed that alogliptin increased HF incidence in patients who had signs of HF at the time of randomization (HR 1.76; 95% CI, 1.07-2.90).57 Hence, data from SAVOR-TIMI 53 and EXAMINE confirmed that DPP-4 inhibitors may increase HF hospitalization in patients with pre-existing HF and high brain natriuretic peptide (BNP) levels at baseline (Table 3).
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
2017, American Journal of MedicineCitation Excerpt :By contrast in the EXAMINE trial, which randomized 5380 T2DM patients with an acute coronary syndrome to receive alogliptin or placebo, the incidence of HF was comparable among the treatment arms (3.1% and 2.9%, respectively).54 However, post hoc analyses showed that alogliptin increased HF incidence in patients who had signs of HF at the time of randomization (HR 1.76; 95% CI, 1.07-2.90).57 Hence, data from SAVOR-TIMI 53 and EXAMINE confirmed that DPP-4 inhibitors may increase HF hospitalization in patients with pre-existing HF and high brain natriuretic peptide (BNP) levels at baseline (Table 3).
Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018)
2018, Clinica e Investigacion en ArteriosclerosisCardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?
2016, Indian Heart JournalCitation Excerpt :Further, for certain findings of a trial, a potential mechanistic explanation may not be available and it may even conflict the current knowledge on the subject. E.g. the increased risk of heart failure in the Saxagliptin arm of SAVOR-TIMI despite a positive effect of GLP-1 on heart failure in animal models.43 Rapid reduction of CV mortality starting within the first year in subjects using empagliflozin in the EMPAREG OUTCOME trial, which conflicts with the known potential glycemic benefits and the known potential CV risk benefits of the drug.13
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
2021, Current Diabetes Reports